NERV Valuation

Minerva Neurosciences Inc

Add to Watchlist

Advanced Chart

2.100

-0.03(-1.408%)1D

Overview
Forecast
Valuation
Earnings

NERV Relative Valuation

NERV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NERV is overvalued; if below, it's undervalued.

Historical Valuation

Minerva Neurosciences Inc (NERV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.06. The fair price of Minerva Neurosciences Inc (NERV) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.13

Fair

-0.86

Trailing

Forward

0.00

EV/EBITDA

Minerva Neurosciences Inc. (NERV) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-2.35

EV/EBIT

Minerva Neurosciences Inc. (NERV) has a current EV/EBIT of -2.35. The 5-year average EV/EBIT is -3.60. The thresholds are as follows: Strongly Undervalued below -10.80, Undervalued between -10.80 and -7.20, Fairly Valued between -0.00 and -7.20, Overvalued between -0.00 and 3.60, and Strongly Overvalued above 3.60. The current Forward EV/EBIT of -2.35 falls within the Historic Trend Line -Fairly Valued range.

0.00

Minerva Neurosciences Inc. (NERV) has a current PS of 0.00. The 5-year average PS is 37.56. The thresholds are as follows: Strongly Undervalued below -193.94, Undervalued between -193.94 and -78.19, Fairly Valued between 153.32 and -78.19, Overvalued between 153.32 and 269.07, and Strongly Overvalued above 269.07. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Minerva Neurosciences Inc. (NERV) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.80. The thresholds are as follows: Strongly Undervalued below -4.40, Undervalued between -4.40 and -2.60, Fairly Valued between 1.00 and -2.60, Overvalued between 1.00 and 2.81, and Strongly Overvalued above 2.81. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Minerva Neurosciences Inc. (NERV) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.65. The thresholds are as follows: Strongly Undervalued below -26.17, Undervalued between -26.17 and -14.91, Fairly Valued between 7.61 and -14.91, Overvalued between 7.61 and 18.87, and Strongly Overvalued above 18.87. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Minerva Neurosciences Inc (NERV) has a current Price-to-Book (P/B) ratio of -0.51. Compared to its 3-year average P/B ratio of -1.49 , the current P/B ratio is approximately -65.71% higher. Relative to its 5-year average P/B ratio of -1.54, the current P/B ratio is about -66.87% higher. Minerva Neurosciences Inc (NERV) has a Forward Free Cash Flow (FCF) yield of approximately -115.50%. Compared to its 3-year average FCF yield of -109.14%, the current FCF yield is approximately 5.83% lower. Relative to its 5-year average FCF yield of -87.29% , the current FCF yield is about 32.31% lower.

-0.51

P/B

Median3y

-1.49

Median5y

-1.54

-115.50

FCF Yield

Median3y

-109.14

Median5y

-87.29

Competitors Valuation Multiple

The average P/S ratio for NERV's competitors is 0.43, providing a benchmark for relative valuation. Minerva Neurosciences Inc Corp (NERV) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NERV.O

Minerva Neurosciences Inc

Allarity Therapeutics Inc

Loss

16.89M

ERNA.O

Ernexa Therapeutics Inc

Pelthos Therapeutics Inc

Neuphoria Therapeutics Inc

Loss

16.34M

Performance Decomposition

Market capitalization of NERV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NERV in the past 1 year is driven by Unknown.